As children return to school, could a biologic offer a safer and more practical way to manage multiple food allergies?

This episode examines new evidence comparing omalizumab with multiallergen oral immunotherapy for multiple food allergies, finding that omalizumab may offer better tolerability and treatment completion. It also reviews the ICECAP trial, which found no neurologic benefit from extending hypothermia after out-of-hospital cardiac arrest, and the SOLARIS trial, in which high-dose vitamin D3 did not improve outcomes in metastatic colorectal cancer.